Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$5.1 million.

  • Rani Therapeutics Holdings' Cash from Operations rose 3979.79% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.7 million, marking a year-over-year increase of 2963.45%. This contributed to the annual value of -$35.5 million for FY2024, which is 3071.28% up from last year.
  • According to the latest figures from Q3 2025, Rani Therapeutics Holdings' Cash from Operations is -$5.1 million, which was up 3979.79% from -$5.8 million recorded in Q2 2025.
  • In the past 5 years, Rani Therapeutics Holdings' Cash from Operations ranged from a high of -$4.0 million in Q1 2021 and a low of -$14.6 million during Q4 2022
  • Moreover, its 5-year median value for Cash from Operations was -$9.4 million (2024), whereas its average is -$9.7 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 175970.15% in 2021, then soared by 4120.11% in 2024.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Cash from Operations stood at -$11.4 million in 2021, then dropped by 27.78% to -$14.6 million in 2022, then increased by 14.7% to -$12.5 million in 2023, then skyrocketed by 30.61% to -$8.7 million in 2024, then surged by 41.53% to -$5.1 million in 2025.
  • Its Cash from Operations was -$5.1 million in Q3 2025, compared to -$5.8 million in Q2 2025 and -$8.1 million in Q1 2025.